Recent studies suggest that metformin, which is a commonly used oral anti-hyperglycemic
agent of the biguanide family, may reduce cancer risk and improve prognosis, yet the …

Recent studies suggest that metformin, which is commonly used as an oral anti-
hyperglycemic agent of the biguanide family, may reduce cancer risk and improve …

Metformin is a commonly used oral anti-hyperglycemic agent of the biguanide family. Recent
studies suggest that metformin may reduce cancer risk and improve prognosis. However, the …

Recent studies suggest that metformin, which is a member of the biguanide family and
commonly used as an oral anti-hyperglycemic agent, may reduce cancer risk and improve …

Metformin known as the first-line orally prescribed drug for lowering blood glucose in type II
diabetes (T2DM) has recently found various therapeutic applications including in cancer …

Despite great improvements in surgical procedures and chemotherapy, pancreatic cancer
remains one of the most aggressive and fatal human malignancies, with a low 5-year …

Esophageal carcinoma is the eighth most common cancer worldwide and the sixth leading
cause of cancer-related deaths, with one of the worst prognoses of any form of cancer …

Metformin is a kind of widely used antidiabetic drug that regulates glucose homeostasis by
inhibiting liver glucose production and increasing muscle glucose uptake. Recently, some …

Cholangiocarcinoma (CCA) is the most common biliary malignancy and the second most
common hepatic malignancy after hepatocellular carcinoma (HCC). Treatment with the anti …

Metformin is one of the most used diabetic drugs for the management of type II diabetes
mellitus (DM) in the world. Increased numbers of epidemiological and clinical studies have …